Summary
A 60-year-old woman with chronic active hepatitis C was treated with 6 million units of rIFN-α2b daily for two weeks and subsequently three times weekly for several months. Histological examination proved a severe form of chronic active hepatitis C unexpectedly complicated with primary biliary cirrhosis (PBC). Before treatment, levels of serum alkaline phosphatase (ALP) or gammaglutamyltranspeptidase (GGT) had remained within normal limits over six months, although anti-mitochondrial antibody (AMA) was shown to be positive. After eight weeks of therapy, the daily dose of rIFN was reduced to 3 million units because of a marked increase of ALP and GGT, although the serum alanine aminotransferase (ALT) was normalized. Four months later, IFN treatment was suspended because of continuous elevation of ursodeoxycholic acid was substituted. Two months later, the ALP and GGT levels returned to the normal range, although ALT was not normalized and HCV-RNA remained positive.
This is the first report case that demonstrates IFN treatment potentially exacerbates PBC associated with chronic active hepatitis C. It is important for treating physicians to keep this association in mind.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Di-Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH: Recombinant alpha interferon therapy for chronic hepatitis C. A randomized, double blind, placebo-controlled trial. N Engl J Med 321:1506–1510, 1989
Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Givas A, Hepatitis Interventional Therapy Group: Treatment of chronic hepatitis with recombinant interferon alpha: A multicenter randomized, controlled trial. N Engl J Med 321:1501–1506, 1989
Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, Coppere H, Cales P, Couzigou P, Benhamou J-P: Recombinant human alpha interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized, controlled trial from France. Hepatology 13:393–397, 1991
Schultz M, Muller R, Von zur Muhlen A, Brabant G: Induction of hyperthyroidism by interferon-alpha-2b. Lancet 1:1452, 1989 (letter)
Mercell P, Pouteau M, Renard P, Grynblat J-M, Colas Linhart N, Bardet P, Bok B, Benhamou J-P: Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C. Gut 33:855–856, 1992
Ronnblom LE, Alm GV, Oberg KE: Autoimmunity after alpha-interferon therapy for malignant carcinoid tumor. Ann Intern Med 115:178–183, 1991
Silva MO, Reddy KR, Jeffers LJ, Hill M, Schiff ER: Interferon-induced chronic hepatitis. Gastroenterology 101:840–842, 1991
Shindo M, Di Bisceglie AM, Hoofnagle JH: Acute exacerbation of liver disease during interferon alpha therapy for chronic hepatitis C. Gastroenterology 102:1406–1408, 1992
Ronnblom LE, Oberg KE, Alm GV: Possible induction of systemic lupus erythematosus by interferon treatment in a patient with a malignant carcinoid tumor. Int J Med 227:207–210, 1990
Abdi EA, Brien W, Venner PM: Auto-immune thrombocytopenia related to interferon therapy. Scand J Haematol 36:515–519, 1986
Pangalis GA, Griva E: Recombinant alpha-2b-interferon therapy in untreated, stages A and B chronic lymphocytic leukemia. Cancer 61:869–872, 1988
Maeda T, Loveland BE, Rowley MJ, Mackay IR: Autoantibody against dihydrolipoamide dehydrogenase, the E3 subunit of the 2-oxoacid dehydrogenase complexes: Significance for primary biliary cirrhosis. Hepatology 14:994–999, 1991
Dawson GJ, Lesniewski RR, Stewart JL, Boardway KM, Gutierrez RA, Pendy L, Johnson RG, Alcalde X, Rote KV, Devare SG: Detection of antibodies to hepatitis C virus in U.S. blood donors. J Clin Microbiol 29:551–556, 1991
Esteban JI, Gonzalez A, Hernandez JE, Vilandomiu L, Sanchez C, Lopes-Talavera C, Lucea D, Martin-Vega C, Vidal X, Esteban R, Guardia J: Evaluation of antibody to hepatitis C virus in a study of transfusion associated hepatitis. N Engl J Med 323:1107–1112, 1990
Kuhnl P, Seidl S, Stangel W, Beyer J, Sibrowski W, Elik J: Antibody to hepatitis C virus in German blood donors. Lancet 2:324, 1989
Watanabe J, Minegishi K, Mitsumori T, Ishifuji M, Oguchi T, Ueda M, Tokunaga E, Tanaka E, Kiyosawa K, Furuta S: Prevalence of anti-HCV antibody in blood donors in the Tokyo area. Vox Sang 59:86–88, 1990
Schattner A: Interferons and autoimmunity. Am J Med Sci 295:523–544, 1988
Farrar WL, Birchenall-Sparks MC, Young HB: Interleukin 2 induction of interferon-gamma in RNA synthesis. J Immunol 127:3836–3840, 1986
Ballardini G, Bianchi FB, Doniach D, Mirakian R, Pisi E, Bottazzo GF: Aberrant expression of HLA-DR antigens on bile duct epithelium in primary biliary cirrhosis: Relevance to pathogenesis. Lancet 2:1009–1113, 1984
Karlsson-Parra A, Burman P, Hagberg H, Oberg K, Alm G, Klareskog L, Karlsson FA: Autoantibodies to epithelial cells in patients on long-term therapy with leukocyte-derived interfer-on-alpha (IFN-α). Clin Exp Immunol 81:72–75, 1990
Mitchison HC, Bassendine MF, Hendrick A, Bennett MK, Bird G, Watoson AJ, James OFW: Positive antimitochondrial antibody but normal alkaline phosphatase: Is this primary biliary cirrhosis? Hepatology 6:1279–1284, 1986
Groote JD, Desmet VJ, Gedigk P, Korb G, Popper H, Poulsen H, Scheuer PJ, Schmid M, Thaler H, Uehlinger E, Wepler W: A classification of chronic hepatitis. Lancet 2:626–628, 1968
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Maeda, T., Onishi, S., Miura, T. et al. Exacerbation of primary biliary cirrhosis during interferon-α2b therapy for chronic active hepatitis C. Digest Dis Sci 40, 1226–1230 (1995). https://doi.org/10.1007/BF02065528
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02065528